Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,esgPopulated,tradeable,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,shortName,exchange,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 29, 2021) 4","Short Ratio (Jun 29, 2021) 4","Short % of Float (Jun 29, 2021) 4","Short % of Shares Outstanding (Jun 29, 2021) 4","Shares Short (prior month May 27, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,GLYC,125123520,51539000,11147236,,-14274059,,-14274059,4188110,1055441,-14279905,-14279905,,,,,,0,1055441,15335346,0,5846,,-14274059,-14274059,448815593,12896383,125123520,138019903,51539,-323743612,373911,1612927,132470624,10842151,2698109,133708867,444568,2140800,50861,-3060,9563938,-1767106,9563938,-4564393,-14125271,68088,1796945,-3060,122866716,en-US,US,EQUITY,True,Delayed Quote,1.8018,1630529863,2.26,0.03999996,0.0,2.2 - 2.36,2.22,0.0,0.0,29,13,finmb_5703481,NasdaqGM,"GlycoMimetics, Inc.",USD,460307,330600,0.44000006,0.24719104,1.78 - 4.4,-2.18,-0.49545455,1.78,4.4,USD,False,False,us_market,2.22,1630526403,0.0,2.26,2.36,2.2,796235,PREPRE,"GlycoMimetics, Inc.",NGM,1620045000,1636029000,1636374600,-1.213,-1.32,-1.23,-1.804878,0,2.428,2.02,0.20000005,0.09900992,2.572971,-0.35297108,-0.13718423,114416584,-1.6818181,0.9143328,15,America/New_York,EDT,-14400000,4,2.12,,,4.4,1.78,2.02,2.573,460.31k,330.6k,51.54M,,31.88M,2.17%,75.49%,1.54M,2.09,3.71%,2.99%,2.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,600.16%",-24.02%,-42.13%,2.22M,0.05,-88.30%,10.16M,-57.41M,-57.64M,-1.2130,,132.47M,2.57,2.6M,2.08,12.33,2.43,-49.87M,-28.2M,Value,20850,Healthcare,54,9,3,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",Rockville,240 243 1201,MD,8,1609372800,1625097600,7,United States,http://glycomimetics.com,86400,8,9708 Medical Center Drive,301 738 2137,Biotechnology
t-1,GLYC,128219456,51539000,11720358,,-15562735,,-15562735,4010920,162935,-15568343,-15568343,,,,,,0,162935,15731278,0,5608,,-15562735,-15562735,437639991,14612713,128219456,142832169,49018,-309469553,264329,1612927,137035017,12428369,2945897,138273345,2149,2089939,1016329,-38175,3888878,2988092,3888878,-5835330,-9686033,68355,1803926,-38175,125844976,en-US,US,EQUITY,True,Delayed Quote,1.8018,1630529863,2.26,0.03999996,0.0,2.2 - 2.36,2.22,0.0,0.0,29,13,finmb_5703481,NasdaqGM,"GlycoMimetics, Inc.",USD,460307,330600,0.44000006,0.24719104,1.78 - 4.4,-2.18,-0.49545455,1.78,4.4,USD,False,False,us_market,2.22,1630526403,0.0,2.26,2.36,2.2,796235,PREPRE,"GlycoMimetics, Inc.",NGM,1620045000,1636029000,1636374600,-1.213,-1.32,-1.23,-1.804878,0,2.428,2.02,0.20000005,0.09900992,2.572971,-0.35297108,-0.13718423,114416584,-1.6818181,0.9143328,15,America/New_York,EDT,-14400000,4,2.12,,,4.4,1.78,2.02,2.573,460.31k,330.6k,51.54M,,31.88M,2.17%,75.49%,1.54M,2.09,3.71%,2.99%,2.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,600.16%",-24.02%,-42.13%,2.22M,0.05,-88.30%,10.16M,-57.41M,-57.64M,-1.2130,,132.47M,2.57,2.6M,2.08,12.33,2.43,-49.87M,-28.2M,Value,20850,Healthcare,54,9,3,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",Rockville,240 243 1201,MD,8,1609372800,1625097600,7,United States,http://glycomimetics.com,86400,8,9708 Medical Center Drive,301 738 2137,Biotechnology
t-2,GLYC,138265728,51539000,10669767,,-13722535,,-13722535,4057530,1000000,-13727297,-13727297,,,,,,0,1000000,14727297,0,4762,,-13722535,-13722535,432124717,12153445,138265728,150419173,47829,-293906818,180117,1612927,142870347,9818355,3163106,145643140,1672,1073610,-291106,-15813,4545416,580826,4545416,-6974243,-11503846,66527,1862442,-15813,135824785,en-US,US,EQUITY,True,Delayed Quote,1.8018,1630529863,2.26,0.03999996,0.0,2.2 - 2.36,2.22,0.0,0.0,29,13,finmb_5703481,NasdaqGM,"GlycoMimetics, Inc.",USD,460307,330600,0.44000006,0.24719104,1.78 - 4.4,-2.18,-0.49545455,1.78,4.4,USD,False,False,us_market,2.22,1630526403,0.0,2.26,2.36,2.2,796235,PREPRE,"GlycoMimetics, Inc.",NGM,1620045000,1636029000,1636374600,-1.213,-1.32,-1.23,-1.804878,0,2.428,2.02,0.20000005,0.09900992,2.572971,-0.35297108,-0.13718423,114416584,-1.6818181,0.9143328,15,America/New_York,EDT,-14400000,4,2.12,,,4.4,1.78,2.02,2.573,460.31k,330.6k,51.54M,,31.88M,2.17%,75.49%,1.54M,2.09,3.71%,2.99%,2.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,600.16%",-24.02%,-42.13%,2.22M,0.05,-88.30%,10.16M,-57.41M,-57.64M,-1.2130,,132.47M,2.57,2.6M,2.08,12.33,2.43,-49.87M,-28.2M,Value,20850,Healthcare,54,9,3,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",Rockville,240 243 1201,MD,8,1609372800,1625097600,7,United States,http://glycomimetics.com,86400,8,9708 Medical Center Drive,301 738 2137,Biotechnology
t-3,GLYC,145752496,51539000,9870813,,-14079029,,-14079029,4234917,0,-14105730,-14105730,,,,,,0,0,14105730,0,26701,,-14079029,-14079029,425890066,12600241,145752496,158352737,46713,-280184283,515144,1612927,149844590,9701289,3381815,153357995,49362,1371308,-1769566,-6383,9579748,-700824,9579748,-4978548,-14551913,67681,1929825,-6383,143656706,en-US,US,EQUITY,True,Delayed Quote,1.8018,1630529863,2.26,0.03999996,0.0,2.2 - 2.36,2.22,0.0,0.0,29,13,finmb_5703481,NasdaqGM,"GlycoMimetics, Inc.",USD,460307,330600,0.44000006,0.24719104,1.78 - 4.4,-2.18,-0.49545455,1.78,4.4,USD,False,False,us_market,2.22,1630526403,0.0,2.26,2.36,2.2,796235,PREPRE,"GlycoMimetics, Inc.",NGM,1620045000,1636029000,1636374600,-1.213,-1.32,-1.23,-1.804878,0,2.428,2.02,0.20000005,0.09900992,2.572971,-0.35297108,-0.13718423,114416584,-1.6818181,0.9143328,15,America/New_York,EDT,-14400000,4,2.12,,,4.4,1.78,2.02,2.573,460.31k,330.6k,51.54M,,31.88M,2.17%,75.49%,1.54M,2.09,3.71%,2.99%,2.77M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,600.16%",-24.02%,-42.13%,2.22M,0.05,-88.30%,10.16M,-57.41M,-57.64M,-1.2130,,132.47M,2.57,2.6M,2.08,12.33,2.43,-49.87M,-28.2M,Value,20850,Healthcare,54,9,3,"GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.",Rockville,240 243 1201,MD,8,1609372800,1625097600,7,United States,http://glycomimetics.com,86400,8,9708 Medical Center Drive,301 738 2137,Biotechnology
